Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
D?josez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz CD. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 2000 Nov; 7(11):1127-36.